RAGE: a novel biological and genetic marker for vascular disease.

RAGE [receptor for AGEs (advanced glycation end-products)] plays an important role in the development and progression of vascular disease. Studies in cultured cells and small animal models of disease have clearly demonstrated that RAGE is central to the pathogenesis of vascular disease of the macro- and micro-vessels in both the diabetic and non-diabetic state. Emerging results from human clinical studies have revealed that levels of circulating soluble RAGE in the plasma may reflect the presence and/or extent of vascular disease state. Additionally, genetic variants of the RAGE gene (AGER in HUGO nomenclature) have been associated with vascular disease risk. Combining RAGE circulating protein levels and the presence of particular RAGE polymorphisms may be a useful clinical tool for the prediction of individuals at risk for vascular disease. Therapeutic intervention targeted at the RAGE gene may therefore be a useful means of treating pathologies of the vasculature.

[1]  C. Molina,et al.  Etiologic Diagnosis of Ischemic Stroke Subtypes With Plasma Biomarkers , 2008, Stroke.

[2]  S. Fukumoto,et al.  Low Circulating Endogenous Secretory Receptor for AGEs Predicts Cardiovascular Mortality in Patients With End-Stage Renal Disease , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[3]  H. Huttunen,et al.  Receptor for Advanced Glycation End Products (RAGE)-mediated Neurite Outgrowth and Activation of NF-κB Require the Cytoplasmic Domain of the Receptor but Different Downstream Signaling Pathways* , 1999, The Journal of Biological Chemistry.

[4]  C. Falcone,et al.  Relationship between the -374T/A RAGE gene polymorphism and angiographic coronary artery disease. , 2004, International journal of molecular medicine.

[5]  C. Heizmann,et al.  N(epsilon)-carboxymethyllysine-modified proteins are unable to bind to RAGE and activate an inflammatory response. , 2008, Molecular nutrition & food research.

[6]  S. Takasawa,et al.  Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. , 2003, The Biochemical journal.

[7]  P. Gane,et al.  The triggering of human peritoneal mesothelial cell apoptosis and oncosis by glucose and glycoxydation products. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  A. Schmidt,et al.  Diabetic vascular disease: it's all the RAGE. , 2005, Antioxidants & redox signaling.

[9]  M. Perola,et al.  The functional -374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients. , 2003, Diabetes.

[10]  Takafumi Yoshida,et al.  Serum Levels of sRAGE, the Soluble Form of Receptor for Advanced Glycation End Products, Are Associated with Inflammatory Markers in Patients with Type 2 Diabetes , 2007, Molecular medicine.

[11]  L. Groop,et al.  The −374 T/A polymorphism in the gene encoding RAGE is associated with diabetic nephropathy and retinopathy in type 1 diabetic patients , 2006, Diabetologia.

[12]  J. Gross,et al.  The -374A allele of the receptor for advanced glycation end products gene is associated with a decreased risk of ischemic heart disease in African-Brazilians with type 2 diabetes. , 2005, Molecular genetics and metabolism.

[13]  A. Schmidt,et al.  Characterization and Functional Analysis of the Promoter of RAGE, the Receptor for Advanced Glycation End Products* , 1997, The Journal of Biological Chemistry.

[14]  T. Kislinger,et al.  Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. , 2001, The American journal of pathology.

[15]  A. Schmidt,et al.  Sp1-binding Elements in the Promoter of RAGE Are Essential for Amphoterin-mediated Gene Expression in Cultured Neuroblastoma Cells* , 1998, The Journal of Biological Chemistry.

[16]  A. Alberts,et al.  The formins: active scaffolds that remodel the cytoskeleton. , 2003, Trends in cell biology.

[17]  Hiroshi Yamamoto,et al.  Development of an ELISA for esRAGE and its application to type 1 diabetic patients. , 2006, Diabetes research and clinical practice.

[18]  K. Kalantar-Zadeh,et al.  Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. , 2003, Kidney international.

[19]  E. Ferrannini,et al.  Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. , 2006, The Journal of clinical endocrinology and metabolism.

[20]  J. Barrett,et al.  RAGE polymorphisms and the heritability of insulin resistance: the Leeds Family Study , 2005, Diabetes & vascular disease research.

[21]  P. Malherbe,et al.  cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein. , 1999, Brain research. Molecular brain research.

[22]  P. Nawroth,et al.  sRAGE and esRAGE are not associated with peripheral or autonomic neuropathy in type 2 diabetes. , 2007, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[23]  M. Andrassy,et al.  Central role of RAGE-dependent neointimal expansion in arterial restenosis. , 2003, The Journal of clinical investigation.

[24]  A. Schmidt,et al.  Activation of the Receptor for Advanced Glycation End Products Triggers a p21 ras -dependent Mitogen-activated Protein Kinase Pathway Regulated by Oxidant Stress* , 1997, The Journal of Biological Chemistry.

[25]  G. Otto,et al.  Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. , 1995, The American journal of pathology.

[26]  P. Guillausseau,et al.  Rapid Publication , 1971, Nature.

[27]  T. Yoshikawa,et al.  Association study of G1704T and G82S polymorphisms of RAGE gene for microalbuminuria in Japanese type 2 diabetic patients. , 2005, Metabolism: clinical and experimental.

[28]  P. Massin,et al.  Severity of diabetic microvascular complications is associated with a low soluble RAGE level. , 2008, Diabetes & metabolism.

[29]  C. Costantini,et al.  The −374A allele of the receptor for advanced glycation end products (RAGE) gene promoter is a protective factor against cardiovascular lesions in type 2 diabetes mellitus patients , 2007, Clinical chemistry and laboratory medicine.

[30]  H. J. Yoo,et al.  Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness. , 2009, International journal of cardiology.

[31]  E. Sahai,et al.  Diaphanous-related formins bridge Rho GTPase and Src tyrosine kinase signaling. , 2000, Molecular cell.

[32]  C. Falcone,et al.  -374T/A polymorphism of the RAGE gene promoter in relation to severity of coronary atherosclerosis. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[33]  HidenoriKoyama,et al.  Low Circulating Endogenous Secretory Receptor for AGEs Predicts Cardiovascular Mortality in Patients With End-Stage Renal Disease , 2007 .

[34]  Merlin C. Thomas,et al.  Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. , 2005, Journal of the American Society of Nephrology : JASN.

[35]  T. Hosoya,et al.  Relationship Between the −374T/A Receptor of Advanced Glycation End Products Gene Polymorphism and Peritoneal Solute Transport Status at the Initiation of Peritoneal Dialysis , 2007, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[36]  E. M. Souza,et al.  The Gly82Ser polymorphism of the receptor of advanced glycation end product (RAGE) gene is not associated with type 1 or type 2 diabetes in a Brazilian population. , 2006, Diabetes care.

[37]  T. Kislinger,et al.  Blockade of RAGE–amphoterin signalling suppresses tumour growth and metastases , 2000, Nature.

[38]  Hiroshi Yamamoto,et al.  De-N-glycosylation or G82S mutation of RAGE sensitizes its interaction with advanced glycation endproducts. , 2007, Biochimica et biophysica acta.

[39]  K. O. Elliston,et al.  Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. , 1992, The Journal of biological chemistry.

[40]  A. Carter,et al.  Identification, classification, and expression of RAGE gene splice variants , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[41]  S. Fukumoto,et al.  Plasma Level of Endogenous Secretory RAGE Is Associated With Components of the Metabolic Syndrome and Atherosclerosis , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[42]  L. Leng,et al.  Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes , 2006, Diabetologia.

[43]  F. Cipollone 741 The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques , 2003 .

[44]  C. Heizmann,et al.  S100B and S100A6 Differentially Modulate Cell Survival by Interacting with Distinct RAGE (Receptor for Advanced Glycation End Products) Immunoglobulin Domains* , 2007, Journal of Biological Chemistry.

[45]  K. Preissner,et al.  The Pattern Recognition Receptor (RAGE) Is a Counterreceptor for Leukocyte Integrins , 2003, The Journal of experimental medicine.

[46]  L. Shuqin,et al.  -429T/C and -374T/A polymorphisms of RAGE gene promoter are not associated with diabetic retinopathy in Chinese patients with type 2 diabetes. , 2003, Diabetes care.

[47]  Y. Zou,et al.  Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. , 1993, The American journal of pathology.

[48]  T. Quertermous,et al.  Molecular Isolation and Characterization of a Soluble Isoform of Activated Leukocyte Cell Adhesion Molecule That Modulates Endothelial Cell Function* , 2004, Journal of Biological Chemistry.

[49]  E. Topol,et al.  Receptor for AGE (RAGE) Mediates Neointimal Formation in Response to Arterial Injury , 2003, Circulation.

[50]  T. Kislinger,et al.  RAGE Blockade Stabilizes Established Atherosclerosis in Diabetic Apolipoprotein E–Null Mice , 2002, Circulation.

[51]  Hiroshi Yamamoto,et al.  The Receptor for Advanced Glycation End Products Is Induced by the Glycation Products Themselves and Tumor Necrosis Factor-α through Nuclear Factor-κB, and by 17β-Estradiol through Sp-1 in Human Vascular Endothelial Cells* , 2000, The Journal of Biological Chemistry.

[52]  J. Traherne,et al.  Review Article doi: 10.1111/j.1744-313X.2008.00765.x Blackwell , 2022 .

[53]  T. Imaizumi,et al.  Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein‐1 (MCP‐1) levels in patients with type 2 diabetes , 2008, Diabetes/metabolism research and reviews.

[54]  A. D'Angelo,et al.  Plasma Levels of Soluble Receptor for Advanced Glycation End Products and Coronary Artery Disease in Nondiabetic Men , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[55]  H. Kaneto,et al.  Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. , 2005, Diabetes care.

[56]  A. Schmidt,et al.  Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts , 1998, Nature Medicine.

[57]  R. Khalifah,et al.  Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. , 1999, Biochemical and biophysical research communications.

[58]  田中 伸茂 The Receptor for Advanced Glycation End Products Is Induced by the Glycation Products Themselves and Tumor Necrosis Factor-α through Nuclear Factor-κB,and by 17β-Estradiol through Sp-1 in Human Vascular Endothelial Cells , 2001 .

[59]  Y. Tomino,et al.  Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function. , 2008, Diabetes research and clinical practice.

[60]  F. Santilli,et al.  Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. , 2007, Free radical biology & medicine.

[61]  G. Norata,et al.  Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. , 2009, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[62]  L. Groop,et al.  Association between LTA, TNF and AGER Polymorphisms and Late Diabetic Complications , 2008, PloS one.

[63]  H. Kaneto,et al.  Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. , 2009, Atherosclerosis.

[64]  C. Heizmann,et al.  Structural and functional insights into RAGE activation by multimeric S100B , 2007, The EMBO journal.

[65]  H. Kaneto,et al.  Serum endogenous secretory RAGE levels are inversely associated with carotid IMT in type 2 diabetic patients. , 2007, Atherosclerosis.

[66]  P. Grant,et al.  Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. , 2001, Diabetes.

[67]  P. Gregersen,et al.  The RAGE Gly82Ser polymorphism is not associated with cardiovascular disease in the Framingham offspring study. , 2005, Atherosclerosis.

[68]  V. Znojil,et al.  Haplotype analysis of the RAGE gene: identification of a haplotype marker for diabetic nephropathy in type 2 diabetes mellitus. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[69]  A. Schmidt,et al.  S100P Stimulates Cell Proliferation and Survival via Receptor for Activated Glycation End Products (RAGE)* , 2004, Journal of Biological Chemistry.

[70]  J. Baynes,et al.  Oxidation of glycated proteins: age-dependent accumulation of N epsilon-(carboxymethyl)lysine in lens proteins. , 1989, Biochemistry.

[71]  R. Ramasamy,et al.  Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. , 2008, The Journal of clinical investigation.

[72]  I. Fajardy,et al.  Human RAGE GLY82SER dimorphism and HLA class II DRB1-DQA1-DQB1 haplotypes in type 1 diabetes. , 1999, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[73]  P. Majumder,et al.  Rage gene promoter polymorphisms and diabetic retinopathy in a clinic-based population from South India , 2007, Eye.

[74]  A. Schmidt,et al.  RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. , 2006, Atherosclerosis.

[75]  K. Herold,et al.  The ligand/RAGE axis: Lighting the fuse and igniting vascular stress , 2006, Current atherosclerosis reports.

[76]  Yee-Ling Wu,et al.  The HLA 8.1 ancestral haplotype is strongly linked to the C allele of -429T>C promoter polymorphism of receptor of the advanced glycation endproduct (RAGE) gene. Haplotype-independent association of the -429C allele with high hemoglobinA1C levels in diabetic patients. , 2007, Molecular immunology.

[77]  K. Herold,et al.  Blockade of RAGE Suppresses Alloimmune Reactions In Vitro and Delays Allograft Rejection in Murine Heart Transplantation , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[78]  T. Imaizumi,et al.  Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. , 2005, Microvascular research.

[79]  Paul J Thornalley Methods for studying the binding of advanced glycated proteins to receptors for advanced glycation endproducts (AGE receptors). , 2002, Methods in molecular biology.

[80]  G. Basta Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications. , 2008, Atherosclerosis.

[81]  X. Chen,et al.  RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease , 1996, Nature.

[82]  出石恭久,et al.  肺におけるReceptor for advanced glycation end productsの存在様式の検討 , 2009 .

[83]  V. D’Agati,et al.  Interaction of the RAGE Cytoplasmic Domain with Diaphanous-1 Is Required for Ligand-stimulated Cellular Migration through Activation of Rac1 and Cdc42* , 2008, Journal of Biological Chemistry.

[84]  J. Chen,et al.  The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin , 1995, The Journal of Biological Chemistry.

[85]  J. Wautier,et al.  Mesothelial RAGE activation by AGEs enhances VEGF release and potentiates capillary tube formation. , 2007, Kidney international.

[86]  T. Hughes,et al.  Divergent pathways of gene expression are activated by the RAGE ligands S100b and AGE-BSA. , 2004, Diabetes.

[87]  R. Muraro,et al.  Suppression of Rage as a Basis of Simvastatin-Dependent Plaque Stabilization in Type 2 Diabetes , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[88]  I. Lednev,et al.  Hexameric Calgranulin C (S100A12) Binds to the Receptor for Advanced Glycated End Products (RAGE) Using Symmetric Hydrophobic Target-binding Patches* , 2006, Journal of Biological Chemistry.

[89]  Y. Zou,et al.  Receptor for Advanced-Glycation End Products: Key Modulator of Myocardial Ischemic Injury , 2006, Circulation.

[90]  A. D'Angelo,et al.  Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. , 2005, Archives of neurology.

[91]  I. Kubota,et al.  Soluble Receptor for advanced glycation end products (RAGE) is a prognostic factor for heart failure. , 2008, Journal of cardiac failure.

[92]  C. Falcone,et al.  The-374T/A Variant of the Rage Gene Promoter is Associated with Clinical Restenosis after Coronary Stent Placement , 2007, International journal of immunopathology and pharmacology.

[93]  M. Neurath,et al.  RAGE Mediates a Novel Proinflammatory Axis A Central Cell Surface Receptor for S100/Calgranulin Polypeptides , 1999, Cell.

[94]  T. Saruta,et al.  Relation between development of nephropathy and the p22phox C242T and receptor for advanced glycation end product G1704T gene polymorphisms in type 2 diabetic patients. , 2004, Diabetes care.

[95]  J. Mužík,et al.  Polymorphisms in the RAGE gene influence susceptibility to diabetes-associated microvascular dermatoses in NIDDM. , 2001, Journal of diabetes and its complications.

[96]  B. Peterlin,et al.  The - 429 T/C and - 374 T/A gene polymorphisms of the receptor of advanced glycation end products gene are not risk factors for diabetic retinopathy in Caucasians with type 2 diabetes. , 2003, Klinische Monatsblatter fur Augenheilkunde.

[97]  J. Ott,et al.  Genetic risk factors for diabetic nephropathy on chromosomes 6p and 7q identified by the set-association approach , 2007, Diabetologia.

[98]  W. Trojaborg,et al.  RAGE modulates peripheral nerve regeneration via recruitment of both inflammatory and axonal outgrowth pathways , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[99]  V. D’Agati,et al.  RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. , 2003, The American journal of pathology.

[100]  P. Grant,et al.  Characterization of allelic and nucleotide variation between the RAGE gene on chromosome 6 and a homologous pseudogene sequence to its 5' regulatory region on chromosome 3: implications for polymorphic studies in diabetes. , 2001, Diabetes.

[101]  Clustering of Long-Term Complications in Families With Diabetes in the Diabetes Control and Complications Trial , 1997, Diabetes.

[102]  A. D'Angelo,et al.  Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension , 2005, Journal of hypertension.

[103]  P. Saftig,et al.  A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane‐bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10) , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[104]  F. Santilli,et al.  Soluble RAGE in type 2 diabetes: association with oxidative stress. , 2007, Free radical biology & medicine.

[105]  I. Meredith,et al.  Cellular adhesion molecules and cardiovascular disease. Part I. Their expression and role in atherogenesis , 2003, Internal medicine journal.

[106]  M. Crow,et al.  Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. , 2001, Diabetes.

[107]  T. Misteli,et al.  Release of chromatin protein HMGB1 by necrotic cells triggers inflammation , 2010, Nature.

[108]  Jerzy K. Kulski,et al.  An update of the HLA genomic region, locus information and disease associations: 2004. , 2004, Tissue antigens.

[109]  E. Vlková,et al.  Polymorphisms 1704G/T, 2184A/G, and 2245G/A in the rage gene are not associated with diabetic retinopathy in NIDDM: pilot study. , 2002, Retina.

[110]  E. Topol,et al.  Genetic susceptibility to myocardial infarction and coronary artery disease. , 2006, Human molecular genetics.

[111]  Jeon-Soo Shin,et al.  Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. , 2004, Molecular immunology.

[112]  T. Yoshikawa,et al.  Relation between polymorphisms G1704T and G82S of rage gene and diabetic retinopathy in Japanese type 2 diabetic patients. , 2005, Internal medicine.

[113]  V. Tesar,et al.  Soluble receptor for advanced glycation end products in patients with decreased renal function. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[114]  P. Ridker,et al.  Polymorphisms in the Advanced Glycosylation End Product–Specific Receptor Gene and Risk of Incident Myocardial Infarction or Ischemic Stroke , 2006, Stroke.

[115]  V. Tesar,et al.  Receptor for advanced glycation end products--soluble form and gene polymorphisms in chronic haemodialysis patients. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[116]  L. Liu,et al.  RAGE Gly82Ser polymorphism in diabetic microangiopathy. , 1999, Diabetes care.

[117]  T. Kislinger,et al.  N ε-(Carboxymethyl)Lysine Adducts of Proteins Are Ligands for Receptor for Advanced Glycation End Products That Activate Cell Signaling Pathways and Modulate Gene Expression* , 1999, The Journal of Biological Chemistry.

[118]  Shitao Li,et al.  Receptor for advanced glycation end products (RAGE) mediates neuronal differentiation and neurite outgrowth , 2008, Journal of neuroscience research.

[119]  V. D’Agati,et al.  Receptor for Advanced Glycation End Products Mediates Inflammation and Enhanced Expression of Tissue Factor in Vasculature of Diabetic Apolipoprotein E–Null Mice , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[120]  P. Rogalla,et al.  Tissue-specific expression patterns of the RAGE receptor and its soluble forms--a result of regulated alternative splicing? , 2003, Biochimica et biophysica acta.

[121]  Takafumi Yoshida,et al.  Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease , 2007, Diabetes/metabolism research and reviews.

[122]  T. Sécher Soluble NCAM , 2008, Neurochemical Research.

[123]  C. Falcone,et al.  The -374T/A RAGE polymorphism protects against future cardiac events in nondiabetic patients with coronary artery disease. , 2008, Archives of medical research.

[124]  I. Fajardy,et al.  Polymorphisms of the receptor of advanced glycation endproducts (RAGE) and the development of nephropathy in type 1 diabetic patients. , 2005, Diabetes & metabolism.

[125]  S. Fukumoto,et al.  Receptor for Advanced Glycation End Products Is Involved in Impaired Angiogenic Response in Diabetes , 2006, Diabetes.

[126]  M. Laakso,et al.  Gly82Ser polymorphism of the receptor of advanced glycation end product gene is not associated with coronary heart disease in Finnish nondiabetic subjects or in patients with type 2 diabetes. , 2000, Diabetes care.

[127]  C. Heizmann,et al.  The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units. , 2007, Biochemistry.

[128]  C. Heizmann,et al.  Calcium-regulated intramembrane proteolysis of the RAGE receptor. , 2008, Biochemical and biophysical research communications.

[129]  H. Kaneto,et al.  Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients , 2008, Diabetes & vascular disease research.

[130]  J. Luban,et al.  Blockade of Late Stages of Autoimmune Diabetes by Inhibition of the Receptor for Advanced Glycation End Products1 , 2004, The Journal of Immunology.

[131]  Saeid Ghavami,et al.  S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase‐dependent pathway , 2008, Journal of leukocyte biology.

[132]  P. Grant,et al.  Identification of polymorphisms in the receptor for advanced glycation end products (RAGE) gene: prevalence in type 2 diabetes and ethnic groups. , 1998, Diabetes.

[133]  P. Gregersen,et al.  RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response , 2002, Genes and Immunity.

[134]  J. Wautier,et al.  AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression. , 2002, Kidney international.

[135]  H. Parving,et al.  Polymorphism screening of four genes encoding advanced glycation end-product putative receptors. Association study with nephropathy in type 1 diabetic patients. , 2001, Diabetes.

[136]  R. Hoffmann,et al.  Structural Basis for Pattern Recognition by the Receptor for Advanced Glycation End Products (RAGE)* , 2008, Journal of Biological Chemistry.

[137]  H. Tse,et al.  Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes , 2007, Diabetologia.

[138]  V. D’Agati,et al.  The biology of RAGE and its ligands: Uncovering mechanisms at the heart of diabetes and its complications , 2007, Current diabetes reports.

[139]  V. D’Agati,et al.  Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. , 2000, Journal of the American Society of Nephrology : JASN.